Purpose: The present chemotherapy in malignancy treatment, including leukaemia, is plagued by one main problem: multidrug resistance (MDR) which is often related to excessive expression of adenosine triphosphate-dependent efflux pump. In recent years, attempts have been focused on searching competitive inhibitors. However, high toxicity and severe side effects were the main impediments for the application of inhibitors.

Methods: this study investigated a new strategy to utilise polyethylene glycol-polylactic-co-glycolic acid-poly-L-lysine (PEG-PLGA-PLL) as a delivery system to combine with gambogic acid (GA) with the purpose of delivering daunorubicin (DNR) to the target location to reserve MDR with maximised therapeutic efficacy and minimised side effects. The anti-tumour ability of DNR in the presence of GA-PEG-PLGA-PLL was evaluated by methyl thiazolyl tetrazolium (MTT) assay, flow cytometry and 4',6-diamidino-2-phenylindole (DAPI) staining. The possible signalling pathway was demonstrated by quantitative real-time polymerase chain reaction (QPCR) and Western blot assay.

Results: The intracellular concentration of DNR can evidently increase with the presence of GA-PEG-PLGA-PLL, and the resistance of K562/A02 cells to DNR can be reversed when combined with GA-PEG-PLGA-PLL, which acted as a delivery system. The anti-tumour efficiency was promoted.

Conclusion: GA-PEG-PLGA-PLL can be a promising agent in reversing MDR of K562/A02 to DNR.

Disclosures

No relevant conflicts of interest to declare.

Topics:
daunorubicin, drug resistance, multiple, nanoparticles, adverse effects, neoplasms, adenosine, cancer, chemotherapy regimen, flow cytometry, glycols

Author notes

*

Asterisk with author names denotes non-ASH members.

© 2015 by The American Society of Hematology
2015
Sign in via your Institution